Lab Medicine Rounds

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Robert Fazzio, M.D., Ph.D., assistant professor of radiology and chair of the Division of Breast Imaging at Mayo Clinic in Rochester, Minnesota.

Timestamps:
0:00 Introduction
1:05 The importance for pathologists to understand the fundamentals of breast imaging.
2:40 Reading the comments and the roles they play in the pathology report.
4:30 Aspects of breast imaging that pathologists should appreciate.
6:45 Interpreting the level of suspicion.
8:00 Modalities for imaging used (ex. Mammograms, ultrasound, MRI)
9:20 Interprofessional collaboration
13:00 Preparation for trainees and various workflows
15:20 Future of breast imaging
18:30 Outro

What is Lab Medicine Rounds?

A Mayo Clinic podcast for laboratory professionals, physicians, and students, hosted by Justin Kreuter, M.D., assistant professor of laboratory medicine and pathology at Mayo Clinic, featuring educational topics and insightful takeaways to apply in your practice.

This is Lab Medicine
Rounds, a curated podcast

for physicians, laboratory
professionals and students.

I'm your host, Justin Kreiter,

a transfusion medicine pathologist

and assistant professor
of laboratory medicine

and pathology at Mayo Clinic.

Today we're rounding with Dr.

Robert Fazio, assistant
professor of radiology

and division chair

of breast Imaging at Mayo Clinic here in

Rochester, Minnesota.

Thanks for joining us today, Dr. Fazio.

Well, thanks so much Dr. Coyer.

This is, this is fantastic.

I've never been part
of one of these before

and so I'm, I'm looking forward to it.

Oh, we're grateful for your time.

I think, you know, I, I
kind of, this topic came up

because I remember fondly
when I was in training

and learning about kind

of doing some breast needle diagnosis

and such, like just remembering

how important the conversation
was with our radiologists.

And so I maybe if we
could kick things off.

I'm kind of curious from your perspective

as a radiologist and,

and really a division
chair of breast imaging,

why is it important, do
you think, for pathologists

to understand a few
fundamentals of breast imaging?

Well, sure, no, I think that's
a, that's a great question.

Really kind of an open-ended
question to get started,

and I'd be interested in your
thoughts as well, you know,

after, after we talk
through this a little bit.

But, you know, I think, I
think that pathologists really,

who understand the basics

of our imaging really might be able

to arrive at their diagnoses faster and,

and with more confidence,
you know, particularly

if the cases are challenging.

I think that both clinical

and imaging information really
about certain cases can be

useful to narrow a differential diagnosis

or even provide a more
confident diagnosis.

You know, you and I are
really both in the fields of,

of turning shades of gray into black

and white answers, you know,
for our clinical colleagues.

And I think imaging knowledge
really can, can help you

make those diagnosis and, and,

and make that challenge happen.

I think, you know, ultimately
our pathologist understanding

of, of imaging fundamentals
can aid in kind

of the confidence of reporting

and also aid in concordance reporting,

which is essential for,
for treatment planning,

particularly in cancer cases.

Wow. You know, that
really resonates with me

because of Exactly, I, I think about the,

the, what's the adage?

The, the pot calling the kettle black.

Sometimes pathologists, we kind
of, you know, put, you know,

great information in our comments

and sometimes our, our colleagues
don't exactly read our,

our comments, just look
at the, what we call the

above the line diagnosis and,

and we're saying like, oh,
didn't you read our, our report?

And I imagine the same thing
is, is true in, in radiology.

And so it's probably, yeah, that impetus

for having a little bit

of fundamental knowledge
probably goes a long way.

Or sometimes we talk
about when is it important

to pick up the phone and call.

Yeah, abso absolutely.

I really, I really actually
enjoy reading the comments.

I, I know that when I see
an extra comment, you know,

below the, the diagnosis,
the official diagnosis,

I know that, you know, that's a case that

that maybe isn't as straightforward

and you guys are thinking
about, you know, thinking out

of the box and doing some
different things to make sure

that your diagnosis is correct.

Y you know, and if I might
ask where, where along in,

in your, you know, training

and development, did you
kind of come to that kind

of realization of, of
kind of the comments and,

and the role that it's
playing in the PATH report?

Sure. Prob I, I suspect probably
in my fellowship is when,

when that sort of hit me a
little bit, I think in residency,

you know, you're all just,
you're just trying to get

through the rotations and do
your best to, you know, to,

to pass the courses and,
and, and pass your exams.

And in fellowship, you
know, you really start

becoming part of the team,
I think, and you contribute

and you provide those contributions.

And so, you know, that's
where I kind of learned that,

that some of these comments might be

even more important than the
actual above comment diagnosis.

Hmm. Wow. I think that's so important.

You know, thinking about
our audience physicians,

laboratory professionals

and students, this kind of
goes to what you're saying,

this kind of interprofessional
understanding

what others on the team are, are doing

and how they're contributing.

Maybe we can dive into that a little bit.

You can kind of, you know, I'm curious,

what are a few aspects of
breast imaging that, you know,

pathologists, it'd be, it'd
be really helpful for them

to appreciate?

Oh, sure, sure. You know, I, I think,

I think there are a few
things that are useful.

I, I think, I think it can
be helpful for pathologists

to understand sort

of the imaging impression
of what we sample.

And as this, I think can help
narrow the differential in

challenging cases.

I, I think it's useful for you guys

to know if we're sampling,
say, a mass lesion

or calcifications or
architectural distortion

or whatnot, you know,

because each of these things
have rather unique imaging

features and it can steer you
down the right pathway when,

when you're having challenges as well.

I think it's useful for
you guys to know our level

of suspicion and also
which modality we're,

we're using for our imaging guidance.

And then finally, I think,
I think it's useful for you

to know how we performed the biopsy.

You know, did we use a
spring loaded device?

Did we use a vacuum assisted device

or did we perform an f n a,
you know, for, for example,

you know, let's say I see
suspicious calcifications on a

mammogram and we go on to
biopsy those calcifications

with vacuum assistance

and get good samples, send calcifications.

And in our impression, you know,

we say high suspicion
calcifications, suspect D C I S,

and you see D C I S I mean,
that's a slam dunk, right?

That's easy. Probably
don't need a comment,

comment
Ab Absolutely.

Where those, where those
things all, all align.

So I guess in the impression that's going

to be in the report, right,

like you're saying mass
calcs architecture,

and you said also that
level of suspicion, how,

how should we interpret or
receive that level of suspicion?

Like is it, is that kind of a, a binary

or should we really try to see that as a,

as a, a shade of gray?

I'm kind of thinking about in
our world of like cytology,

you know, there is kind of specific words

that are used in this
kind of shade of, of gray

and how should we kind of interpret that?

Sure, sure. Well, usually
when I send a clinical

impression, I'll indicate
high intermediate

or low Suspicion and then
whatever it is that I'm sampling.

And, and so I try to, I try

to make it a little bit black and white.

I don't give high or low, I
just high intermediate or low.

If I'm pretty confident
this is gonna be D C I S

for example, and,

and I say high suspicion calcifications

and you, you report back
fibrocystic changes, then you

and I need to have a phone
conversation probably.

And, and so I, I try to, I try

to make it a little bit black

and white for you guys as well.

Oh, that's helpful. And can
you elaborate a little bit on

you, you mentioned that
modality is for what type

of imaging is used

and how that might be helpful

for the pathologist to understand.

Can you kind of elaborate
on what you mean by that?

'cause as an outsider, I'm
not sure if I'm really kind

of picking up what you're talking about.

Oh, absolutely, absolutely.

So, you know, the common modalities

that we use are mammograms,
ultrasound, and M R i.

Those are probably the top three.

And so if we're biopsying
something with mammogram guidance,

and so that would be something
like a stereotactic breast

biopsy or a tomosynthesis
guided breast biopsy.

You know, you're, we're we're
usually aiming at something

that could be D C I S or not.

Could it be invasive or
microinvasive? Absolutely.

But, but when we're doing
a, a stereotactic biopsy,

we're thinking about D C I S the most.

Whereas if we're using ultrasound

or m r I guidance, we're
probably targeting a mass.

And so that could be invasive malignancy

or any of the benign masses that that,

that can be diagnosed in the breast.

And so that's sort of,
that's sort of what I mean

by useful to know kind of the modality.

Ah, no, that, that's very helpful.

You know, we've been
kind of playing around

with this idea of kind

of this interprofessional
collaboration, like you said,

in certain situations, you know, we need

to have a phone call
and, and talk things out.

You know, knowing that
the, the audience here,

we have a lot of pathologists and

and lab medicine folks that
are listening to this and,

and students along the pathway
of hopefully playing this,

this team sport of medicine.

You know, what are your thoughts on

how pathologists could better
collaborate with radiologists?

And I, I really ask this
question 'cause sometimes

it's hard to know how do I
get started collaborating

with an outside group?

And so, you know, your insights
here are really appreciated.

Oh, absolutely. You know, first

and foremost, I really do
think our collaboration efforts

are, are fantastic.

And particularly in the clinical arena,

we really are the only
subspecialty that works

with the breast pathologists

that perform concordance
reporting on our biopsy samples.

I don't think anybody else does that.

And so I, I think that our collaboration

between our groups really,
really facilitates this,

the ability to do that.

Otherwise, you know, as you
mentioned on the clinical side,

I think phone conversations
are always helpful.

If you guys are con
confused about the material

that we send, certainly
happy to take a conversation

or if we can provide any
additional, you know,

information about what you might be seeing

in a challenging case, happy, happy

to discuss it at any time.

You know, in addition, we're,

we're starting our radiology

patho pathology concordance
conference backup.

This is a conference
that we run each week.

Our fellows run it,

and we like to get as many people there

as possible from the
multidisciplinary team,

but particularly radiologists
and pathologists.

So to sort of discuss some

of the more challenging
cases that we biopsied,

maybe the week previous
covid really kind of hit

that conference hard

and we sort of, it just sort

of went away for about three years.

But, but our current
fellows are really excited

to start it back up and
we're, we're starting

to do those conferences again.

I, I still remember, you know, some very,

very eager pathology fellows
that came to those conferences.

They, they even bring
PowerPoints with slides about,

you know, the, the biopsy findings.

And it was really, really useful.

That was maybe four or five years ago,

but you know, that that
conference was really beneficial

to our trainees and I think
to your trainees as well.

And we'd love, we'd love
for you guys to, to come

to those conferences again

and I'm, I'm happy to
try to facilitate that.

Yeah, that's fantastic and great

for our audience to hear, right?

'cause we have a lot of
audience outside of Mayo

and they might be kind
of thinking about how,

how is this kind of play
out in their own area?

Some may have these
conferences that are going

or some might have some
like ours where Covid kind

of gave us a little bit
of a, a pause and a skip.

I'm kind of curious,
you know, there's a lot,

because we have our,
our student listeners,

I'd be curious to kind of
just hear your thoughts on,

you know, how for these kind

of interprofessional conferences, right?

That's, that's where like
I think you're highlighting

some important learning is happening for

how your radiology
trainees are interacting

with pathology trainees,
pathology consultants.

Are, are there any thoughts
you've had over the years

for either, you know, how do
you kind of prepare people

for going into these environments

or are there kind of some common feedbacks

that you've given to
trainees over the years

to learn the most from these
sorts of collaborations?

Yeah, I mean, I, I think,
I think there's a lot

of good kind

of on the fly discussion
at these meetings that

that can be beneficial to, to teach

the interdisciplinary team
about the others fields.

You know, ideally we would
have breast pathology fellows

rotate with us to visit our
procedural practice as well.

I, I'm not sure if that's
happening right now.

I think it has happened in the past.

We, we do send our fellows to you

and they're very, very
complimentary of those weeks just

to see, you know, see

what they've biopsied
under the microscope and,

and how that compares to, you know, all

of the other breast pathologies out there.

So rotating,

I think in the other
subspecialty is really helpful.

Yeah, I think that's been wonderful.

As I've, you know, talking with
our trainees over the years,

this idea that they understand
kind of the workflow

with the other groups
so they can understand

where sometimes various pressures come up

and certainly goes a long
way for, you know, if, if you

and I have have met in, in
real life and shared a laugh

or whatnot, like it, it makes it easier

to pick up the phone and have those,

those critical conversations.

Yeah. I also think it's
really, really useful.

I mean, if there's an interesting
case that, that they can,

you know, write up very quickly.

I mean, case reports
can happen pretty fast

and you know, if you have
a, a collaborative team on

that between two fellows

or two residents, I think those
are fantastic opportunities.

Oh, absolutely.

And you know, I'm grateful
that you're highlighting how

what might be originally perceived

as maybe a clinical practice arena thing,

a clinical domain,

how it's filling roles
in both education as well

as the research shield.

I I think that's a true statement.

Can I maybe close with just
kinda asking you, you know,

how might breast imaging change
in the, in the coming years?

I think a lot of our audience
aren't necessarily, you know,

don't, don't have your
vantage point and perspectives

and, and curious what
you see in the coming

years for breast imaging.

Sure, sure. I, I think it's
an exciting time to be honest.

I, I think that there
could be some changes in

how screening is performed.

You know, right now everybody
gets an annual mammogram

starting at age 40 and you know,

going into their eighties and nineties

and every year they have
to attend that mammogram.

And you know, we detect a lot of,

of tiny cancers on those
mammograms now in the future,

and people are working on this right now,

but I think that there
may be opportunities

for blood tests as
initial screening tools.

Patients would get
their annual blood test.

Those that are negative
would be done for the rest

of the year until their next annual test.

Those that are positive
would end up coming to us to,

to get diagnostic imaging rather
than a screening mammogram.

The other thing I think
could be exciting is

that there are a lot of
developments in M R I right now

and abbreviated m r I might be the future

of screening as well.

It's much more sensitive and
specific than mammography is.

The trouble with, with m r I really is

that the machines cost a lot.

You know, that the exams
take a long time to perform.

Patients need to have an
IV placed with contrast.

And so if we can get
by some of those things

and make the examination shorter
to perform, I think that's,

I think it has potential for sure.

I think AI will be a, a,

a factor in helping us provide
diagnoses in the future.

We're still working to try
to figure out the best way

to incorporate AI into our practice.

You're probably doing the same thing.

I really hope that imaging
specificity will improve, which,

you know, would decrease really the need

for biopsies in many cases.

I've thought that this
would happen for years

and so far it hasn't happened.

We do as many biopsies now
as we have 10 years ago when,

when I started on staff.

A couple other things. I think,

I think image guided
percutaneous therapies like

cryoablation has potential to reduce

open surgical treatment.

I think that has a, a future.

But, you know, having said,
having said all that, I I,

I do think that image guided
biopsies are not going

away anytime soon.

And so you and I will have many years

of collaboration ahead of us.

I think

I'm really looking forward to that and,

and I really appreciate it is really

quite an extensive list.

You're, you're sharing with our listeners,

which I I'm sure for that
there's at least something

that's kind of planted in
every listener's mind in

that list that you mentioned.

We've been rounding with Dr.

Fazio talking about
fundamentals of breast imaging

and what pathologists need to know.

Thanks for joining us today, Dr. Fazio.

Absolutely. Dr. Corder, thanks
so much for the invitation.

And to all our listeners,
thank you for joining us today.

We invite you to share your thoughts

and suggestions via email

to MCL education@mayo.edu.

If you've enjoyed this
podcast, please subscribe

until our next rounds together.

We encourage you to continue
to connect lab medicine

and the clinical practice through
educational conversations.